Anti-Ms CD62L FITC

Anti-Ms CD62L FITC
Regulatory status
RUO
Antigen
CD62L
Clone
Mel-14
Format
FITC
Reactivity
Mouse
Application
FC (QC tested)
Excitation laser
blue (488 nm)
Variant
0.1 mg
1F-626-C100
In stock
Variant
0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Rat IgG2a
Specificity
The rat monoclonal antibody MEL-14 reacts with mouse CD62L (L-selectin), a 75 kDa single chain type I glycoprotein expressed on most peripheral blood B lymphocytes, T lymphocytes, monocytes and granulocytes; it is also present on a subset of NK cells and certain hematopoietic malignant cells.
Application
FC (QC tested)
Reactivity
Mouse
Immunogen
C3H/eb mouse B cell lymphoma 38C-13
Other names
L-selectin, Lsel, Sell, Lam-1, Lam1, Lecam, Leu8, Lnhr, Lyam1, Plnhr
Preparation
The purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

Product specific references:

Richards H, Longhi MP, Wright K, Gallimore A, Ager A: CD62L (L-selectin) down-regulation does not affect memory T cell distribution but failure to shed compromises anti-viral immunity. J Immunol. 2008 Jan 1;180(1):198-206.
PubMed
Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ: Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood. 2004 Feb 15;103(4):1534-41.
PubMed
Xu H, Manivannan A, Crane I, Dawson R, Liversidge J: Critical but divergent roles for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammation. Blood. 2008 Aug 15;112(4):1166-74.
PubMed
Friedline RH, Wong CP, Steeber DA, Tedder TF, Tisch R: L-selectin is not required for T cell-mediated autoimmune diabetes. J Immunol. 2002 Mar 15;168(6):2659-66.
PubMed
Gallatin WM, Weissman IL, Butcher EC: A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 1983 Jul 7;304:30-34.
PubMed
Brawand P, Cerottini JC, MacDonald HR: Hierarchal utilization of different T-cell receptor Vbeta gene segments in the CD8(+)-T-cell response to an immunodominant Moloney leukemia virus-encoded epitope in vivo. J Virol. 1999 Nov;73(11):9161-9.
PubMed
Fisson S, Darrasse-Jèze G, Litvinova E, Septier F, Klatzmann D, Liblau R, Salomon BL: Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med. 2003 Sep 1;198(5):737-46.
PubMed
ten Bruggencate SJ, Hillyer LM, Woodward BD: The proportion of CD45RA(+)CD62L(+) (quiescent-phenotype) T cells within the CD8(+) subset increases in advanced weight loss in the protein- or energy-deficient weanling mouse. J Nutr. 2001 Dec;131(12):3266-9.
PubMed
Mannering SI, Cheers C: Interleukin-2 and loss of immunity in experimental Mycobacterium avium infection. Infect Immun. 2002 Jan;70(1):27-35.
PubMed
Pop SM, Wong CP, He Q, Wang Y, Wallet MA, Goudy KS, Tisch R: The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes. 2007 May;56(5):1395-402.
PubMed
Chin CS, Miller CH, Graham L, Parviz M, Zacur S, Patel B, Duong A, Bear HD: Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. Int Immunol. 2004 Sep;16(9):1283-94.
PubMed
Variant
0.1 mg
1F-626-C100
In stock
Variant
0.1 mg
11-261-C100
In stock